Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
240 questions in 36 reviews · Dementia and Cognitive Improvement
current versionsNo studies 240 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo Activities of daily living Mean change from baseline using the ADCS Mild Cognitive Impairment Activities of Daily Living Scale from: 0 to 53 · people with mild cognitive impairment Vitamin E for Alzheimer's dementia and mild cognitive impairment (2017) · Cochrane | no estimate extracted | NR | No studies |
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin Global cognitive function · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin Incidence of MCI · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin Incidence of dementia · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin Adverse events (Hypoglycaemia) · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Rosiglitazone plus metformin vs glibenclamide (glyburide) plus metformin Mortality · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide (glyburide) vs Repaglinide Incidence of MCI · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide (glyburide) vs Repaglinide Incidence of dementia · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide (glyburide) vs Repaglinide Adverse events (Hypoglycaemia) · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Glibenclamide (glyburide) vs Repaglinide Mortality · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Intensive glycaemic control vs standard glycaemic control Incidence of MCI · patients with Type 2 diabetes Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia (2017) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic cholinesterase inhibitor vs placebo Return to independent living ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic cholinesterase inhibitor vs placebo Inpatient mortality ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Return to independent living ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Inpatient mortality ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Return to independent living ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Bispectral index (BIS)‐guided anaesthesia vs BIS‐blinded anaesthesia/clinical judgement Duration of delirium ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Bispectral index (BIS)‐guided anaesthesia vs BIS‐blinded anaesthesia/clinical judgement Severity of delirium ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Bispectral index (BIS)‐guided anaesthesia vs BIS‐blinded anaesthesia/clinical judgement Return to independent living ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Bispectral index (BIS)‐guided anaesthesia vs BIS‐blinded anaesthesia/clinical judgement In‐hospital mortality ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic cholinesterase inhibitor vs placebo Duration of delirium ‐ not measured Interventions for preventing delirium in hospitalised non‐ICU patients (2016) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 PUFA supplements vs placebo Memory ‐ not measured · people with mild to moderate Alzheimer's disease Omega‐3 fatty acids for the treatment of dementia (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incident dementia ‐ not measured · adults with cognitive impairment/dementia and cognitively intact populations Antihypertensive withdrawal for the prevention of cognitive decline (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Falls ‐ not measured · adults with cognitive impairment/dementia and cognitively intact populations Antihypertensive withdrawal for the prevention of cognitive decline (2016) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs no respite care Rate of institutionalisation · patients with people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs polarity therapy Physical health of people with dementia ‐ not reported · people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs polarity therapy Quality of life of people with dementia ‐ not reported · people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs polarity therapy Caregiver burden ‐ not reported · people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs no respite care Mortality of people with dementia ‐ not reported · patients with people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs no respite care Physical health of people with dementia ‐ not reported · patients with people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs no respite care Quality of life of people with dementia ‐ not reported · patients with people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs no respite care Caregiver quality of life ‐ not reported · patients with people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs polarity therapy Rate of institutionalisation ‐ not reported · people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Respite care vs polarity therapy Mortality of people with dementia ‐ not reported · people with dementia and their carers Respite care for people with dementia and their carers (2014) · Cochrane | no estimate extracted | NR | No studies |
Cognitive rehabilitation vs control Change in rates of admission to residential care－not measured · participants with early‐stage Alzheimer's disease and vascular dementia Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (2013) · Cochrane | no estimate extracted | NR | No studies |
Cognitive rehabilitation vs control Change in measures of dementia severity－not measured · participants with early‐stage Alzheimer's disease and vascular dementia Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (2013) · Cochrane | no estimate extracted | NR | No studies |
Cognitive training vs control Change in rates of admission to residential care－not measured · participants with early‐stage Alzheimer's disease and vascular dementia Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (2013) · Cochrane | no estimate extracted | NR | No studies |
Cognitive training vs control Change in measures of dementia severity－not measured · participants with early‐stage Alzheimer's disease and vascular dementia Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (2013) · Cochrane | no estimate extracted | NR | No studies |
Cognitive rehabilitation vs control Change in a global measure of cognition－not measured · participants with early‐stage Alzheimer's disease and vascular dementia Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia (2013) · Cochrane | no estimate extracted | NR | No studies |
procaine vs placebo overall changes from baseline in "healthy persons7 ‐ not measured · "healthy" old persons and demented women Procaine treatments for cognition and dementia (2008) · Cochrane | no estimate extracted | NR | No studies |